Presenter: David Stamler, M.D., CEO of Alterity Therapeutics ...
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. For example, the ...
Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
Fintel on MSN
Alterity Therapeutics Limited - Depositary Receipt (ATHE) price target decreased by 35.66% to 4.27
The average one-year price target for Alterity Therapeutics Limited - Depositary Receipt (NasdaqCM:ATHE) has been revised to $4.27 / share. This is a decrease of 35.66% from the prior estimate of ...
Hosted on MSN
Is Alterity Therapeutics Limited (ATHE) the Best Australian Stock to Buy According to Analysts?
We recently published a list of the 11 Best Australian Stocks to Buy According to Analysts. In this article, we are going to take a look at where Alterity Therapeutics Limited (NASDAQ:ATHE) stands ...
Alterity announces board changes ahead of its AGM, positioning biotech for next growth phase Founding shareholder, former CEO and current non-executive chairman Geoffrey Kempler retires CEO Dr David ...
Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program - - Positive feedback supports readiness for Phase 3 initiation with manufacturing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results